Healthcare Industry News: dilatation catheter
News Release - June 9, 2008
OrbusNeich Receives CE Mark Approval for Scoreflex(TM) Coronary Dilatation CatheterHONG KONG, June 9 (HSMN NewsFeed) -- OrbusNeich today announced that it has received CE Mark approval for the Scoreflex coronary dilatation catheter.
The new product, which rounds out OrbusNeich's balloon catheter portfolio, is designed for use in focused force angioplasty, a technique in which the force resulting from balloon inflation in a stenotic lesion is concentrated at one or more locations within the stenosis. Published research has shown that focused force angioplasty is effective in resolving resistant stenosis while reducing the frequency of complications with its use of gradual, low-pressure inflations.
"Scoreflex has helped me prepare the vessel better prior to stent deployment," said Dato' Dr. Rosli Mohd Ali, head of the Cardiology Department, National Heart Institute, Kuala Lumpur, Malaysia. "It also has the potential to achieve good angiographic results when compared to using a regular balloon in treating bifurcation lesions and lesions affecting small vessels."
The Scoreflex dual wire system creates a focal stress pattern to facilitate effective controlled plaque fracture at low-resolution pressure. In addition to its effective dilatation, Scoreflex has a low crossing profile and unbeatable trackability. OrbusNeich expects the rapid adoption and integration of the balloon catheter into interventional cardiologists' practices.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.